Forest Laboratories, Inc. Receives Subpoena on Benicar®, Benicar HCT® and Azor®
May 09 2011 - 4:07PM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) announced that it received
a subpoena from the Office of the U.S. Attorney for the District of
Massachusetts dated April 20, 2011. The subpoena requests documents
relating to Benicar®, Benicar HCT® (collectively “Benicar”) and
Azor®, prescription medications approved for the treatment of
hypertension. Forest co-marketed Benicar from 2002 to 2008 together
with their originator Daiichi Sankyo, Inc. pursuant to co-promotion
agreements. The Company intends to cooperate in responding to the
subpoena.
About Forest
Laboratories
Forest Laboratories’ (NYSE:FRX) longstanding global partnerships
and track record developing and marketing pharmaceutical products
in the United States have yielded its well-established central
nervous system and cardiovascular franchises and innovations in
anti-infective and respiratory medicine. The Company’s pipeline,
the most robust in its history, includes product candidates in all
stages of development across a wide range of therapeutic areas. The
Company is headquartered in New York, NY. To learn more, visit
www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories’ Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, and any subsequent SEC filings.
Benicar®, Benicar HCT® and Azor® are registered trademarks of
Daiichi Sankyo, Inc.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024